Research Presented at ASM Microbe 2017: Study of a Drug Candidate, Mul-1867, for Inhalation Therapy of Fungal Pneumonia Caused by Clinical Isolates of Aspergillus fumigatus in a Murine Lung Infection Model

June 4, 2017
NEW ORLEANS, June 4, 2017 — A next-generation antibiotic being developed by researchers at the New York-based pharmaceutical company TGV-inhalonix is significantly more effective than traditional drugs in fighting the rise in airway pathogens that cause life-threatening lung infections caused by multiresistant Aspergillus spp. from cystic fibrosis patients, according to research presented today at ASM Microbe 2017.

George Tetz, drug development advisor for TGV-inhalonix detailed their findings on TGV-inhalonix’s inhaled antifungal, Mul-1867, in an abstract at poster accepted for presentation at the conference, which boasts the world’s largest gathering of microbiologists.

“Mul-1867 is a breakthrough, novel drug candidate that we believe holds considerable promise in prevention and treatment the chronic and rising number of antibiotic-resistant infections that often prove fatal for immunocompromised patients,” Tetz said.

The abstract and paper detailed a study comparing Mul-1867 to the drug amphotericin B. The researchers said their results proved Mul-1867 to be significantly more effective, completely preventing and eradicating the fungal biofilms of the highly drug-resistant airway pathogens Aspergillus spp.
“Aspergillus spp causes lung infection in mice with 100% mortality in untreated control. We revealed that Mul-1867 was more active than Amphotericin B in both PROPHYLACTIC and TREATMENT regimens in in vivo models. Mul-1867 completely (100%) protected animals from pneumonia related mortality when it was used before and up to 80% when after the fungal challenge” the abstract said. “Fungal infections predominantly caused by Aspergillus spp. are the most common cause of mortality in lung transplant recipients and occur in up to 35% of recipients in this patient group”.
Tetz said Mul-1867 also offers broader potential for the treatment of various bacterial and fungal infections in patients with compromised immune systems and the general population, including respiratory tract infections in Cystic fibrosis patients, ventilator-associated pneumonia and fungal pneumonia.

The new study results were released just 3 days before George Tetz, chief scientific advisor at TGV-inhalonix, will give an oral presentation to the European Cystic Fibrosis Conference about a separate study indicating Mul-1867 provides 90 percent and greater protection against mortality from lung infections caused by MRSA/VRSA.

“While there are a number of new drugs being tested to fight the chronic lung infections that plague cystic fibrosis patients, Mul-1867 is the first drug candidate under development that holds promise against multiple strains of bacteria, as well those infections cause by a mix of bacteria and fungi,” George Tetz said.

Cystic fibrosis is a progressive, genetic disease that causes mucus buildup that clogs the airways and traps bacteria, leading to infections, extensive lung damage and eventually, respiratory failure. According to the Cystic Fibrosis Foundation, the median predicted survival age in persons with cystic fibrosis in the United States is 39.3 years.

The U.S. Food and Drug Administration recently granted Mul-1867 Orphan Drug Designation based on early indications of its potential for fighting lung infections in cystic fibrosis patients. The special status is intended to provide incentives for the development of drugs and biologics to treat rare diseases.